MYRIAD GENETICS, INC. Payments to Acquire Available-for-sale Securities
MYRIAD GENETICS, INC. (MYGN) reported Payments to Acquire Available-for-sale Securities of $80.90 million for the 12-month period ending 2018-06-30, per its 10-K filed 2018-08-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-08-24
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $1.50M, a 88.37% decline year-over-year.
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $18.10M, a 29.30% decline year-over-year.
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $29.80M, a 77.38% increase year-over-year.
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $31.50M, a 2.17% decline year-over-year.
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for fiscal 2018 was $80.90M, a 7.54% decline from fiscal 2017.
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for fiscal 2017 was $87.50M, a 46.81% decline from fiscal 2016.
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for fiscal 2016 was $164.50M, a 103.84% increase from fiscal 2015.
- MYRIAD GENETICS, INC. payments to acquire available-for-sale securities for fiscal 2015 was $80.70M, a 50.12% decline from fiscal 2014.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-06-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | $19.60M derived: sum of 2 quarters · filed 2018-08-24 | $49.40M derived: sum of 3 quarters · filed 2018-08-24 | $80.90M 10-K · filed 2018-08-24 |
| 2018-03-31 | $18.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $47.90M derived: sum of 2 quarters · filed 2018-05-09 | $79.40M 10-Q · filed 2018-05-09 | $92.30M derived: sum of 4 quarters · filed 2018-08-24 |
| 2017-12-31 | $29.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-07 | $61.30M 10-Q · filed 2018-02-07 | $74.20M derived: sum of 3 quarters · filed 2018-08-24 | $99.80M derived: sum of 4 quarters · filed 2018-08-24 |
| 2017-09-30 | $31.50M 10-Q · filed 2017-11-08 | $44.40M derived: sum of 2 quarters · filed 2018-08-24 | $70.00M derived: sum of 3 quarters · filed 2018-08-24 | $86.80M derived: sum of 4 quarters · filed 2018-08-24 |
| 2017-06-30 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | $38.50M derived: sum of 2 quarters · filed 2018-08-24 | $55.30M derived: sum of 3 quarters · filed 2018-08-24 | $87.50M 10-K · filed 2018-08-24 |
| 2017-03-31 | $25.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $42.40M derived: sum of 2 quarters · filed 2018-05-09 | $74.60M 10-Q · filed 2018-05-09 | $107.70M derived: sum of 4 quarters · filed 2018-08-24 |
| 2016-12-31 | $16.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-07 | $49.00M 10-Q · filed 2018-02-07 | $82.10M derived: sum of 3 quarters · filed 2018-08-24 | $112.80M derived: sum of 4 quarters · filed 2018-08-24 |
| 2016-09-30 | $32.20M 10-Q · filed 2017-11-08 | $65.30M derived: sum of 2 quarters · filed 2018-08-24 | $96.00M derived: sum of 3 quarters · filed 2018-08-24 | $174.90M derived: sum of 4 quarters · filed 2018-08-24 |
| 2016-06-30 | $33.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | $63.80M derived: sum of 2 quarters · filed 2018-08-24 | $142.70M derived: sum of 3 quarters · filed 2018-08-24 | $164.50M 10-K · filed 2018-08-24 |
| 2016-03-31 | $30.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-03 | $109.60M derived: sum of 2 quarters · filed 2017-05-03 | $131.40M 10-Q · filed 2017-05-03 | $157.00M derived: sum of 4 quarters · filed 2017-08-09 |
| 2015-12-31 | $78.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | $100.70M 10-Q · filed 2017-02-08 | $126.30M derived: sum of 3 quarters · filed 2017-08-09 | $158.80M derived: sum of 4 quarters · filed 2017-08-09 |
| 2015-09-30 | $21.80M 10-Q · filed 2016-11-02 | $47.40M derived: sum of 2 quarters · filed 2017-08-09 | $79.90M derived: sum of 3 quarters · filed 2017-08-09 | $96.60M derived: sum of 4 quarters · filed 2017-08-09 |
| 2015-06-30 | $25.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-09 | $58.10M derived: sum of 2 quarters · filed 2017-08-09 | $74.80M derived: sum of 3 quarters · filed 2017-08-09 | $80.70M 10-K · filed 2017-08-09 |
| 2015-03-31 | $32.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-04 | $49.20M derived: sum of 2 quarters · filed 2016-05-04 | $55.10M 10-Q · filed 2016-05-04 | |
| 2014-12-31 | $16.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-03 | $22.60M 10-Q · filed 2016-02-03 | ||
| 2014-09-30 | $5.90M 10-Q · filed 2015-11-04 | |||
| 2014-06-30 | $161.80M 10-K · filed 2016-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |